SCHEMBL20753263

SCHEMBL20753263

OCC(O)CSSc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MGLL Q99685 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ADRA2A P08913 1/20 0.35
ADRA2B P18089 1/20 0.35
ADRA2C P18825 1/20 0.35
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
CYP1A2 P05177 3/20 0.33
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 3/20 0.33
LMNA P02545 2/20 0.33
MAPK1 P28482 1/20 0.33
AGTR1 P30556 1/20 0.33
FFAR1 O14842 1/20 0.32
MTNR1A P48039 3/20 0.32
MTNR1B P49286 3/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycerin SCHEMBL27724190 0.81 HPGD (0.55) MAPTHPGDSMN1; SMN2MGLLHSD17B10
SCHEMBL1496771 0.79 MAOA (0.50) MAPTMAOAMAOBALDH1A1MAPK1
SCHEMBL6543393 0.79 MAOA (0.50) MAPTMAOAMAOBALDH1A1MAPK1
SCHEMBL6482093 0.79 MAOA (0.50) MAPTMAOAMAOBALDH1A1MAPK1
SCHEMBL26530635 0.74 CYP2C9 (0.38) MAPTHPGDSMN1; SMN2MGLLHSD17B10
SCHEMBL29201828 0.73 HPGD (0.55) MAPTHPGDSMN1; SMN2MGLLHSD17B10
SCHEMBL28594156 0.73 EHMT2 (0.52) MAPTHPGDCYP1A2KDM4EALDH1A1
SCHEMBL576229 0.72 SMN1; SMN2 (0.48) MAPTHPGDSMN1; SMN2MGLLHSD17B10
SCHEMBL12390061 0.72 IDO1 (0.36) ADRA2AADRA2BADRA2CCYP2C19CA1
SCHEMBL20150448 0.70 SMN1; SMN2 (0.50) MAPTHPGDSMN1; SMN2MGLLHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111032669-B Orthoester compositions for affinity purification of oligonucleotides 安捷伦科技有限公司 2024-03-29 CN disclosed
US-20230322742-A1 ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES AGILENT TECHNOLOGIES, INC. 2023-10-12 US disclosed
US-20230322742-A1 ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES AGILENT TECHNOLOGIES, INC. 2023-10-12 US disclosed
US-20230122968-A1 ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES AGILENT TECHNOLOGIES, INC. 2023-04-20 US disclosed
US-11548876-B2 Orthoester compositions for affinity purification of oligonucleotides AGILENT TECHNOLOGIES, INC. (US) 2023-01-10 US disclosed
US-11548876-B2 Orthoester compositions for affinity purification of oligonucleotides AGILENT TECHNOLOGIES, INC. (US) 2023-01-10 US disclosed
US-11299483-B2 Orthoester compositions for affinity purification of oligonucleotides AGILENT TECHNOLOGIES, INC. (US) 2022-04-12 US disclosed
US-11299483-B2 Orthoester compositions for affinity purification of oligonucleotides AGILENT TECHNOLOGIES, INC. (US) 2022-04-12 US disclosed
US-20200190129-A1 ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES AGILENT TECHNOLOGIES, INC. 2020-06-18 US disclosed
US-20200190129-A1 ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES AGILENT TECHNOLOGIES, INC. 2020-06-18 US disclosed
US-20200181124-A1 ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES AGILENT TECHNOLOGIES, INC. 2020-06-11 US disclosed
US-20200181124-A1 ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES AGILENT TECHNOLOGIES, INC. 2020-06-11 US disclosed
CN-111032669-A Ortho ester compositions for affinity purification of oligonucleotides 安捷伦科技有限公司 2020-04-17 CN disclosed
WO-2019036029-A1 ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES AGILENT TECHNOLOGIES, INC. (US) 2019-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200190129-A1 ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES RNGTT, OSBPL8, DCLRE1B MAPT 1562/4885HPGD 4773/4885SMN1; SMN2 1046/4885
US-20230122968-A1 ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES RNGTT, DCLRE1B, MRTO4 MAPT 1375/4885HPGD 4636/4885SMN1; SMN2 1151/4885
US-20200181124-A1 ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES RNGTT, OSBPL8, DCLRE1B MAPT 1562/4885HPGD 4773/4885SMN1; SMN2 1046/4885
US-11548876-B2 Orthoester compositions for affinity purification of oligonucleotides RNGTT, OSBPL8, DCLRE1B MAPT 1562/4885HPGD 4773/4885SMN1; SMN2 1046/4885
US-20230322742-A1 ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES RNGTT, OSBPL8, DCLRE1B MAPT 1562/4885HPGD 4773/4885SMN1; SMN2 1046/4885
US-11299483-B2 Orthoester compositions for affinity purification of oligonucleotides RNGTT, OSBPL8, DCLRE1B MAPT 1562/4885HPGD 4773/4885SMN1; SMN2 1046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.